We See an In-Line or Better Q2 & Think Full-Year Sales & EPS Guidance Will Hold

Research evidence excerpt

We See an In-Line or Better Q2 & Think Full-Year Sales & EPS Guidance Will Hold

TD Cowen Boston Scientific

Global Research July 14, 2026

AT A GLANCE

Our Investment Thesis Forthcoming Catalysts

Helped by a leadership change made a decade ago, Boston Scientific has decreased its ■ Ongoing rollout of Exalt-D

dependence on commoditized cardiac rhythm management devices and drug-eluting ■ Continued commercial traction for

stents and now has a diversified high-growth product portfolio. We remain optimistic on the Watchman FLX

company’s current drivers and planned launches, which include Watchman FLX, Acurate neo2, ■ Pipeline progress with the EP portfolio,

the drug-eluting peripheral technology, Lux-Dx, Farapulse, single-use scopes, LithoVue and Acurate neo2, and the leadless

Rezum, among others. pacemaker, among other programs

Base Case Assumptions Upside Scenario Downside Scenario

■ Performing in-line with sales and EPS ■ Exceeding sales and EPS guidance and ■ Underperforming sales and EPS guidance

guidance and tracking in line with longer- tracking ahead of longer-term guidance and tracking below longer-term guidance

term guidance ■ Making faster-than-anticipated pipeline ■ Making slower-than-anticipated pipeline

■ Making routine pipeline progress progress progress

Price Performance Company Description

Boston Scientific develops, manufactures and markets medical devices that are utilized in a

$120

wide range of interventional procedures. The company’s seven core businesses are organized

110 into three reporting segments: MedSurg (comprising Endoscopy and Urology and Pelvic

Health), Rhythm and Neuro (comprising CRM, Electrophysiology and Neuromodulation) and 100

Cardiovascular (comprising Interventional Cardiology and Peripheral Interventions). BSX sells